Cargando…
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibit...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825274/ https://www.ncbi.nlm.nih.gov/pubmed/24282816 http://dx.doi.org/10.1155/2013/467869 |
_version_ | 1782290791324975104 |
---|---|
author | Salam, Kazi Abdus Akimitsu, Nobuyoshi |
author_facet | Salam, Kazi Abdus Akimitsu, Nobuyoshi |
author_sort | Salam, Kazi Abdus |
collection | PubMed |
description | Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors as well as host targeted inhibitors. Two NS3-4A protease inhibitors (telaprevir and boceprevir) have been recently approved for the treatment of hepatitis C in combination with standard of care (pegylated interferon plus ribavirin). The new therapy has significantly improved sustained virologic response (SVR); however, the adverse effects associated with this therapy are still the main concern. In addition to the emergence of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase portion of the HCV NS3 protein. This review article summarizes our current understanding of HCV treatment, particularly with those of NS3 inhibitors. |
format | Online Article Text |
id | pubmed-3825274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-38252742013-11-26 Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives Salam, Kazi Abdus Akimitsu, Nobuyoshi Biomed Res Int Review Article Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors as well as host targeted inhibitors. Two NS3-4A protease inhibitors (telaprevir and boceprevir) have been recently approved for the treatment of hepatitis C in combination with standard of care (pegylated interferon plus ribavirin). The new therapy has significantly improved sustained virologic response (SVR); however, the adverse effects associated with this therapy are still the main concern. In addition to the emergence of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase portion of the HCV NS3 protein. This review article summarizes our current understanding of HCV treatment, particularly with those of NS3 inhibitors. Hindawi Publishing Corporation 2013 2013-10-27 /pmc/articles/PMC3825274/ /pubmed/24282816 http://dx.doi.org/10.1155/2013/467869 Text en Copyright © 2013 K. A. Salam and N. Akimitsu. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Salam, Kazi Abdus Akimitsu, Nobuyoshi Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives |
title | Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives |
title_full | Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives |
title_fullStr | Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives |
title_full_unstemmed | Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives |
title_short | Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives |
title_sort | hepatitis c virus ns3 inhibitors: current and future perspectives |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825274/ https://www.ncbi.nlm.nih.gov/pubmed/24282816 http://dx.doi.org/10.1155/2013/467869 |
work_keys_str_mv | AT salamkaziabdus hepatitiscvirusns3inhibitorscurrentandfutureperspectives AT akimitsunobuyoshi hepatitiscvirusns3inhibitorscurrentandfutureperspectives |